{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":">/= Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":">/= Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":">/= Minimal Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Determine the overall response rate per the modified uniform response criteria of the International Myeloma Working Group (IMWG), partial response and better. Partial Remission (PR): \\>/= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>/= 90% or to \\< 200 mg per 24 hours; Very Good Partial Remission (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hours; Complete Remission (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\</= 5% plasma cells in bone marrow.","groups":[{"description":"Combination Therapy: Phase I Dose Escalation followed by Phase 2 treatment at Recommended Phase 2 Dose (RP2D)","id":"OG000","title":"Selinexor, Liposomal Doxorubicin and Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants treated at recommended phase 2 dose, regardless of when they joined the study.","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Overall Response Rate (ORR) -All Participants Treated at Recommended Phase 2 Dose","type":"PRIMARY","unitOfMeasure":"Participants"}